AbbVie has entered a partnership and option-to-license agreement with Xilio for tumour-activated, antibody-based ...

The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...

The funding will be used to complete the Phase II/III trial of ulviprubart, and to support commercial launch preparation.

Lundbeck has received the US FDA fast track designation for amlenetug, a potential treatment for multiple system atrophy (MSA ...

GlobalData’s Revati Tatake discussed key trends in biopharma which are set to have an impact in 2025 and beyond.

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.